T he improving survival of patients with metastatic bone disease translates into increased disease prevalence that has resulted in a rising cost of care. Our goals as physicians should be to not only alleviate the burden on our patients but also to minimize any unnecessary burden on the healthcare system. In the United States, caring for the more than 250,000 patients who have metastatic bone disease comes at an annual cost of USD 12 billion [1] . Hence, as orthopaedic surgeons, when we consider surgical treatment of these patients, we must do so with an increasing eye on the precise indications for prophylactic fixation as well as the potential morbidity of any surgical intervention. We should strive to only operate prophylactically on patients who truly have impending fractures and on those who are likely to have a better result with prophylactic treatment compared to treating the fracture after the fact.
One area of increased scrutiny during the last several years has been the delineation of precise imaging-based indications for prophylactic fixation of impending fractures. Newer techniques, such as CT-based structural rigidity analysis (CTRA), finite element modeling (FEM), and fluorodeoxyglucose positron emission tomography (FDG-PET) CT have been shown to be more accurate in predicting impending fractures than the traditional Harrington and Mirels methods [2, 3, [5] [6] [7] . But generally, these techniques are not financially feasible, which limit their availability. Of course, using imaging to identify bone lesions that are biomechanically impending fractures is only part of the equation. Other important variables include patient's level of pain, disease prognosis, expected response to alternate therapies, comorbidities, and personal goals.
Moreover, the risk of treatment complications, as illustrated in the current study [4] , should be considered to ensure that prophylactic treatment is at the least not worse than treating the fracture after the fact. In the current study, McLynn and colleagues [4] present their National Surgical Quality Improvement Program (NSQIP)-based complication analysis for the femoral shaft and more distal femur. They found that when controlled for differences in patient characteristics, patients who underwent prophylactic stabilization benefited only in terms of a lower likelihood of transfusion compared to patients treated after a pathologic fracture occurred. The high overall complication (18%), major complication (14%), and death rates (7%) of the prophylactically treated group showed that the risks of prophylactic stabilization are not worse than that of treatment after fracture, and that the advantages are minimal [4] . Obviously, there are some situations where, owing to debilitating 
Where Do We Need To Go?
The current study leaves two questions unanswered. First, are we operating on too many patients for lesions that are not truly impending pathologic fractures? The NSQIP analysis data set does not provide details as to how the decision for prophylactic fixation was made, so we don't know what percentage of the patients who were prophylactically stabilized actually had impending fractures by well-defined imaging indications.
The likelihood of fracture may not be as high as we think. In the prospective Musculoskeletal Tumor Society (MSTS) study evaluating patients with bone lesions for possible impending pathologic fracture using CTRA, 32 patients with 40 lesions underwent prophylactic stabilization [2] . Of the remaining 78 patients (94 lesions) followed prospectively without prophylactic stabilization to endpoints of either 1 year or death, only six patients (six lesions) sustained fractures [2] . It seems that with a moreprecise definition of impending pathologic fracture, most patients with lesions would not need operative treatment to prevent fracture since they are not at increased risk.
Second, is the patient reported pain and functional outcome, risk profile, and cost-effectiveness of our prophylactic surgical treatment better in terms of pain relief, improved function, lower complications, and better costeffectiveness than if we had simply treated them nonoperatively? In the current study, the authors compared prophylactically surgically treated patients to those treated surgically after the fracture, but the third undiscussed group is those with possible impending fractures who were treated nonoperatively. Again, the NSQIP database does not provide access to any of the aforementioned details of that group, and the authors acknowledge this. Since nonoperative treatment of patients with possible impending pathologic fractures by other modalities such as radiotherapy, bisphosphonates, chemotherapy, hormonal therapies, or immunomodulation may obviate the need for surgery, it may also eliminate the risks associated with surgery that McLynn and colleagues [4] have documented. With an apparently low risk of overall fracture in this group, as suggested in the MSTS study [2] , it is concerning that the risk of complications following prophylactic stabilization is comparable to that of those who already had fractures. For those patients who have not yet fractured, it would seem logical that we should carefully select a treatment-operative or nonoperative-that is not just equivalent to that of operative treatment after fracture but rather superior to such treatment.
How Do We Get There?
Prophylactic stabilization for patients with metastatic disease to bone can be gratifying both for patient and physician when pain is severe and/or recalcitrant to other treatments, but we must make sure that these prophylactic procedures are both effective and safe. Continued work is needed in this area.
The focus moving forward should be on: (1) Using precise impending fracture pathologic imaging definitions and (2) exploring not only the operatively treated patients (prophylactic and postfracture) but also the nonoperatively treated group in our research. With respect to the former, these newer technologies will evolve with time and hopefully become widely available and accepted. Regarding the latter, three possibilities come to mind. First, those patients enrolled in the CTRA study and treated nonoperatively may be compared to those treated prophylactically in terms of complications in the operative group versus fracture and similar complications in the initially nonoperatively treated group, matching for patients deemed to be high or low risk by CTRA. The second will require more time, but as the more precise imaging techniques of CTRA, FEM, and FDG PET/CT are employed, parallel longitudinal data collection should include operative and nonoperative complications, patient-reported outcome measures, survival, cost, and fracture occurrence in the nonoperatively treated group. But it's not easy to get the major funding necessary to adequately evaluate and employ these techniques on a widespread basis. From the standpoint of developing the individual techniques, CTRA is closest to being thoroughly evaluated and made widely available. The third will require cooperation with radiation and medical oncologists; together we should create longitudinally maintained databases not only of our surgical patients with metastatic disease, but also of those treated without surgery.
